Skip to main content

Cilastatin / imipenem / relebactam Side Effects

Medically reviewed by Drugs.com. Last updated on Jan 20, 2024.

Applies to cilastatin / imipenem / relebactam: intravenous powder for solution.

Serious side effects

Along with its needed effects, cilastatin/imipenem/relebactam may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking cilastatin / imipenem / relebactam:

More common

Less common

Incidence not known

Other side effects

Some side effects of cilastatin / imipenem / relebactam may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

For Healthcare Professionals

Applies to cilastatin / imipenem / relebactam: intravenous powder for injection.

Hepatic

Very common (10% or more): Increased AST (up to 11.7%)

Common (1% to 10%): Increased ALT

Imipenem-cilastatin:

-Common (1% to 10%): Increased ALT, increased AST

-Uncommon (0.1% to 1%): Increased serum bilirubin

-Rare (0.01% to 0.1%): Hepatic failure, hepatitis

-Very rare (less than 0.01%): Fulminant hepatitis

-Frequency not reported: Jaundice[Ref]

Hematologic

Very common (10% or more): Anemia (included anemia, decreased hemoglobin; up to 10.5%)

Frequency not reported: Thrombocytopenia

Imipenem-cilastatin:

-Common (1% to 10%): Anemia, eosinophilia

-Uncommon (0.1% to 1%): Pancytopenia, neutropenia, leukopenia, thrombocytopenia, thrombocytosis, positive Coombs test, prolonged prothrombin time, decreased hemoglobin

-Rare (0.01% to 0.1%): Agranulocytosis

-Very rare (less than 0.01%): Hemolytic anemia, bone marrow depression

-Frequency not reported: Increased eosinophils, increased eosinophil count[Ref]

Metabolic

Common (1% to 10%): Hypokalemia (included hypokalemia, decreased blood potassium), hyponatremia (included hyponatremia, decreased blood sodium)

Gastrointestinal

Common (1% to 10%): Diarrhea, nausea, vomiting, increased lipase, constipation

Frequency not reported: Clostridioides difficile-associated diarrhea

Imipenem-cilastatin:

-Common (1% to 10%): Nausea, diarrhea, vomiting, increased lipase

-Rare (0.01% to 0.1%): Pseudomembranous colitis, staining of teeth and/or tongue

-Very rare (less than 0.01%): Gastroenteritis, hemorrhagic colitis, abdominal pain, heartburn, glossitis, tongue papilla hypertrophy, increased salivation[Ref]

Dermatologic

Common (1% to 10%): Rash (included rash, erythematous rash, generalized rash)

Imipenem-cilastatin:

-Common (1% to 10%): Rash (e.g., exanthematous)

-Uncommon (0.1% to 1%): Urticaria, pruritus

-Rare (0.01% to 0.1%): Toxic epidermal necrolysis, angioedema, Stevens-Johnson syndrome, erythema multiforme, exfoliative dermatitis

-Very rare (less than 0.01%): Hyperhidrosis, skin texture changes[Ref]

Other

Common (1% to 10%): Pyrexia

Imipenem-cilastatin:

-Common (1% to 10%): Pyrexia, increased serum alkaline phosphatase

-Rare (0.01% to 0.1%): Candidiasis

-Very rare (less than 0.01%): Chest discomfort, asthenia/weakness

-Frequency not reported: Increased blood lactate dehydrogenase[Ref]

Nervous system

Common (1% to 10%): Headache

Uncommon (0.1% to 1%): Central nervous system (CNS) adverse reactions (included agitation, apathy, confusional states, delirium, disorientation, slow speech, somnolence)

Imipenem-cilastatin:

-Common (1% to 10%): Headache, CNS adverse reactions

-Uncommon (0.1% to 1%): Seizures, myoclonic activity, dizziness, somnolence

-Rare (0.01% to 0.1%): Encephalopathy, paresthesia, focal tremor, taste perversion, hearing loss

-Very rare (less than 0.01%): Aggravation of myasthenia gravis, vertigo, tinnitus

-Frequency not reported: Dyskinesia[Ref]

Local

Common (1% to 10%): Phlebitis/infusion site reactions (included infusion site phlebitis, infusion site erythema, infusion site pain)

Imipenem-cilastatin:

-Common (1% to 10%): Phlebitis/infusion site reactions

-Uncommon (0.1% to 1%): Local pain and induration at injection site[Ref]

Cardiovascular

Common (1% to 10%): Hypertension (included hypertension, increased blood pressure)

Imipenem-cilastatin:

-Common (1% to 10%): Hypertension, thrombophlebitis

-Uncommon (0.1% to 1%): Hypotension

-Very rare (less than 0.01%): Cyanosis, tachycardia, palpitations, flushing[Ref]

Renal

Uncommon (0.1% to 1%): Increased blood creatinine, decreased creatinine renal clearance

Imipenem-cilastatin:

-Common (1% to 10%): Increased blood creatinine

-Uncommon (0.1% to 1%): Increased blood urea nitrogen

-Rare (0.01% to 0.1%): Acute renal failure[Ref]

Psychiatric

Imipenem-cilastatin:

-Uncommon (0.1% to 1%): Hallucinations, confusional states

-Frequency not reported: Agitation[Ref]

Hypersensitivity

Imipenem-cilastatin:

-Rare (0.01% to 0.1%): Anaphylactic reactions

Beta-lactams:

-Frequency not reported: Hypersensitivity (anaphylactic) reactions[Ref]

Genitourinary

Imipenem-cilastatin:

-Rare (0.01% to 0.1%): Oliguria/anuria, polyuria, urine discoloration

-Very rare (less than 0.01%): Pruritus vulvae[Ref]

Urine discoloration was harmless (not to be confused with hematuria).[Ref]

Respiratory

Imipenem-cilastatin:

-Very rare (less than 0.01%): Dyspnea, hyperventilation, pharyngeal pain[Ref]

Musculoskeletal

Imipenem-cilastatin:

-Very rare (less than 0.01%): Polyarthralgia, thoracic spine pain[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Recarbrio (imipenem/cilastatin/relebactam). Merck & Co., Inc. 2019.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.